Semaglutide under 18: what the UK licence means for young people

You've found a page about Wegovy and your child isn't 18 yet

It's a reasonable search to make. Watching a teenager struggle with weight (especially when adults around them are being prescribed weekly injections and seeing results) can feel deeply unfair. The honest answer, though, is that the MHRA licence for semaglutide (Wegovy) in weight management explicitly covers adults only. That isn't a bureaucratic technicality; it reflects a genuine absence of robust safety and efficacy data in the under-18 age group for this indication in the UK context.

The STEP 1 trial that underpinned Wegovy's approval enrolled adults aged 18 and over, as documented in the STEP 1 paper published in the New England Journal of Medicine. There is no equivalent adequately powered trial in UK-licensed paediatric populations for semaglutide as a weight-loss treatment. When a medicine hasn't been studied in a population, its safety profile in that population is simply unknown, and that uncertainty is why the licence exists where it does.

If a young person is struggling with their weight, the right first call is their GP. NICE guideline NG246 covers overweight and obesity management across the life course, and paediatric pathways involve specialist teams, school health services and dietitians rather than GLP-1 prescribing. You can read the full NICE obesity management guideline for context on how clinicians approach this for younger patients.

What happens at 18, and why it isn't automatic

Turning 18 doesn't unlock semaglutide the next day. Age is one criterion, not the whole picture. The licensed eligibility for Wegovy injection requires a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as hypertension, prediabetes or obstructive sleep apnoea. The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, carries similar adult-only eligibility criteria.

A prescriber also looks at the broader clinical picture: other medicines, any history of conditions that interact with GLP-1 therapy, and whether the person is ready to combine treatment with dietary and activity changes. At nume, every application is personally read by a GPhC-registered Independent Prescriber on the same day, a real clinician, not a queue for automated software. If you or a young person in your care will shortly turn 18, it can be worth reading our dedicated guidance on Wegovy for under-18s so you understand what a future assessment might involve.

Pregnancy, breastfeeding and actively trying to conceive are separate reasons semaglutide is not recommended regardless of age. If any of those situations apply, you can find out more about how semaglutide affects pregnancy, what the risks involve, and what to do if your circumstances change before going further.

Red flags: what a legitimate UK prescriber will never do

No GPhC-registered UK pharmacy or MHRA-regulated prescriber will supply Wegovy for weight management to someone under 18. If you encounter a website or social media account offering to do so (especially without asking for a proper consultation and age verification) that is a serious red flag. The MHRA has warned repeatedly about fake and illegally traded weight-loss pens sold online, and under-18s searching for weight-loss medicines are a particularly vulnerable audience for those sellers.

You can verify any online pharmacy using the GPhC pharmacy register; a legitimate service will have a registered premises number you can look up there. Suspected illegal sellers can be reported via the MHRA Yellow Card scheme. If a teenager has already obtained semaglutide through an unverified route and is experiencing side effects, treat it as a medical matter and contact a GP or NHS 111 promptly.

For background on cardiovascular considerations that sometimes come up in family discussions about GLP-1 medicines, our page covering what semaglutide does to heart rate and the licensed adult evidence behind those effects covers this clearly.

If you're close to 18 and want to know what comes next

The most useful thing you can do before turning 18 is talk to your GP. They can assess your weight-related health, flag any conditions that might affect eligibility, and help you understand whether a GLP-1 medicine is likely to be appropriate once you reach adulthood. That conversation also creates a medical record your future prescriber can draw on.

If NHS access is an option, the NHS England weight management injections page sets out the eligibility criteria and wraparound care requirements honestly. Private assessment through a regulated service becomes available from your 18th birthday, subject to clinical suitability. Our weight loss treatment overview explains what's licensed for adults and how the process works. And if you have questions that don't fit neatly anywhere, including whether drinking alcohol on semaglutide is something you need to think about, our FAQs or the support team are there.